Health benefits: Some physicians employ this as a way to sedate hysterical events, inhibit microbial and bacterial growth, treat rheumatism and arthritis, as a protection against sepsis, tightening gums and muscles. Furthermore, pennyroyal essential oil helps prevent hair loss and hemorrhaging, clears congestion and eases breathing, purifies blood, facilitates digestion, opens obstructed menstruation and makes them regular, while also killing and repelling insects.
CBD oil contains CBD (and often other active compounds) in a carrier oil. There are a number of forms of CBD oil, including softgel capsules, tinctures, and under-the-tongue sprays. Some forms of CBD oil can also be applied directly to the skin, in the form of products like creams and salves. The concentration of CBD varies from product to product.
Copaiba oil has anti-inflammatory properties and is often marketed as a treatment for arthritis, however most of the evidence for its efficacy comes from rodent studies. A 2017 review published in Integrative Medicine pointed out that copaiba had not yet been tested in a randomized trial against a placebo in human arthritis patients or tested in comparison to anti-inflammatory medications.
Some essential oils should not be taken orally. Most bottles will indicate if the oil is intended for oral or topical use. Essential oils that can be ingested need to be correctly diluted and dosed. Never swallow essential oils from the bottle. If you want to try taking peppermint oil for indigestion or lemon balm oil for stress, buy supplement capsules from a reputable brand and do not exceed the recommended daily dose.
Nabiximols (brand name Sativex) is a patented medicine containing CBD and THC in equal proportions. The drug was approved by Health Canada in 2005 for prescription to treat central neuropathic pain in multiple sclerosis, and in 2007 for cancer related pain. In New Zealand Sativex® is approved for use as an add-on treatment for symptom improvement in patients with moderate to severe spasticity due to Multiple Sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.